These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19855161)

  • 21. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
    Le Tourneau C; Faivre S; Serova M; Raymond E
    Br J Cancer; 2008 Oct; 99(8):1197-203. PubMed ID: 18797463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular and molecular effects of the mTOR inhibitor everolimus.
    Saran U; Foti M; Dufour JF
    Clin Sci (Lond); 2015 Nov; 129(10):895-914. PubMed ID: 26330617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.
    Liu P; Ge M; Hu J; Li X; Che L; Sun K; Cheng L; Huang Y; Pilo MG; Cigliano A; Pes GM; Pascale RM; Brozzetti S; Vidili G; Porcu A; Cossu A; Palmieri G; Sini MC; Ribback S; Dombrowski F; Tao J; Calvisi DF; Chen L; Chen X
    Hepatology; 2017 Jul; 66(1):167-181. PubMed ID: 28370287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus (RAD001) ameliorates vascular cognitive impairment by regulating microglial function via the mTORC1 signaling pathway.
    Chen L; Zhang Y; Li D; Zhang N; Liu R; Han B; Wei C; Liu H; Xu X; Hao J
    J Neuroimmunol; 2016 Oct; 299():164-171. PubMed ID: 27725116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting the role of mTOR: lessons from mTOR inhibitors.
    Dowling RJ; Topisirovic I; Fonseca BD; Sonenberg N
    Biochim Biophys Acta; 2010 Mar; 1804(3):433-9. PubMed ID: 20005306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting translation in acute myeloid leukemia: a new paradigm for therapy?
    Tamburini J; Green AS; Chapuis N; Bardet V; Lacombe C; Mayeux P; Bouscary D
    Cell Cycle; 2009 Dec; 8(23):3893-9. PubMed ID: 19934662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repression of Mammalian Target of Rapamycin Complex 1 Inhibits Intestinal Regeneration in Acute Inflammatory Bowel Disease Models.
    Guan Y; Zhang L; Li X; Zhang X; Liu S; Gao N; Li L; Gao G; Wei G; Chen Z; Zheng Y; Ma X; Siwko S; Chen JL; Liu M; Li D
    J Immunol; 2015 Jul; 195(1):339-46. PubMed ID: 26026060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
    Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
    Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders.
    Neasta J; Ben Hamida S; Yowell Q; Carnicella S; Ron D
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20093-8. PubMed ID: 21041654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
    Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
    Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.
    Wall M; Poortinga G; Stanley KL; Lindemann RK; Bots M; Chan CJ; Bywater MJ; Kinross KM; Astle MV; Waldeck K; Hannan KM; Shortt J; Smyth MJ; Lowe SW; Hannan RD; Pearson RB; Johnstone RW; McArthur GA
    Cancer Discov; 2013 Jan; 3(1):82-95. PubMed ID: 23242809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of mTOR signaling affects cone function, cone structure and expression of cone specific proteins without affecting cone survival.
    Ma S; Venkatesh A; Langellotto F; Le YZ; Hall MN; Rüegg MA; Punzo C
    Exp Eye Res; 2015 Jun; 135():1-13. PubMed ID: 25887293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
    Johnston PB; Inwards DJ; Colgan JP; Laplant BR; Kabat BF; Habermann TM; Micallef IN; Porrata LF; Ansell SM; Reeder CB; Roy V; Witzig TE
    Am J Hematol; 2010 May; 85(5):320-4. PubMed ID: 20229590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
    Mabuchi S; Altomare DA; Connolly DC; Klein-Szanto A; Litwin S; Hoelzle MK; Hensley HH; Hamilton TC; Testa JR
    Cancer Res; 2007 Mar; 67(6):2408-13. PubMed ID: 17363557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
    Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
    Faes S; Duval AP; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Demartines N; Dormond O
    Mol Cancer; 2016 Dec; 15(1):78. PubMed ID: 27919264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of GSK3 cellular location by FRAT modulates mTORC1-dependent cell growth and sensitivity to rapamycin.
    He L; Fei DL; Nagiec MJ; Mutvei AP; Lamprakis A; Kim BY; Blenis J
    Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19523-19529. PubMed ID: 31492813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes.
    Veilleux A; Houde VP; Bellmann K; Marette A
    Mol Endocrinol; 2010 Apr; 24(4):766-78. PubMed ID: 20203102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.